| Balance sheet (USD) | Q2 2026 ended Jun 30, 2026 | Q1 2026 ended Mar 31, 2026 | Q4 2025 ended Dec 31, 2025 | Q3 2025 ended Sep 30, 2025 | Q2 2025 ended Jun 30, 2025 | Q1 2025 ended Mar 31, 2025 | Q4 2024 ended Dec 31, 2024 | Q3 2024 ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.18B | 7.63B | 7.56B | 7.33B | 5.14B | 7.93B | 9.99B | 5.04B |
| Short-term investments | 0 | 15.00M | 68.00M | 19.00M | 69.00M | 0 | 0 | |
| Receivables | 5.05B | 4.74B | 4.91B | 5.09B | 4.78B | 4.39B | 4.42B | 4.59B |
| Inventory | 1.95B | 1.91B | 1.77B | 1.78B | 1.82B | 1.76B | 1.71B | 1.87B |
| Total current assets | 13.95B | 18.64B | 18.34B | 17.87B | 14.72B | 16.90B | 19.17B | 14.78B |
| Property, plant and equipment | 5.83B | 5.64B | 5.61B | 5.50B | 5.46B | 5.42B | 5.41B | 5.39B |
| Goodwill and intangibles | 22.35B | 24.70B | 25.29B | 26.28B | 26.88B | 27.67B | 28.26B | 28.86B |
| Total assets | 49.36B | 56.28B | 59.02B | 58.53B | 55.72B | 56.43B | 58.99B | 54.52B |
| Accounts payable | 674.00M | 645.00M | 715.00M | 808.00M | 582.00M | 737.00M | 833.00M | 903.00M |
| Total current liabilities | 11.02B | 9.48B | 11.81B | 12.30B | 11.19B | 12.34B | 12.00B | 11.72B |
| Long-term debt | 23.83B | 20.86B | 22.13B | 22.14B | 22.14B | 22.15B | 24.90B | 21.44B |
| Total liabilities | 37.53B | 32.76B | 36.32B | 36.99B | 36.05B | 37.27B | 39.66B | 36.05B |
| Retained earnings | 2.20B | 14.13B | 13.73B | 12.82B | 11.32B | 10.93B | 11.50B | 11.07B |
| Shareholders' equity | 11.83B | 23.52B | 22.70B | 21.54B | 19.67B | 19.16B | 19.33B | 18.48B |
| Total debt | 26.25B | 22.17B | 24.94B | 24.94B | 24.95B | 24.95B | 26.71B | 23.25B |
| Net debt | 23.07B | 14.55B | 17.37B | 17.61B | 19.80B | 17.03B | 16.72B | 18.21B |
From Gilead Sciences's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read balance sheet or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.